Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More BICX Press!
https://www.investing.com/analysis/naloxone-and-naltrexone:-anti-drug-addiction-stocks-to-watch-200176440
With the drug addiction treatment market being about $35 billion a year in the U.S. alone, it is easy to understand why the industry is rapidly becoming a popular space.
Big pharmaceutical companies, like Insys Therapeutics Inc (NASDAQ:INSY), Pfizer Inc. (NYSE:PFE), Amphastar P (NASDAQ:AMPH), Mylan N.V. (NASDAQ:MYL), Opiant Technologies Inc. (OPNT), Adapt Pharma Ltd., Kaleo Pharmaceuticals, Alkermes Plc (NASDAQ:ALKS), and newcomer Biocorrx Inc (OTC:BICX) are all jockeying for position to get a bigger slice of the market.
Brady Granier, President, CEO and Director of BioCorRx, commented, “This epidemic is showing no signs of slowing and more options are needed for treatment and prevention. It is a very large market that is showing some signs of consolidation within the treatment center space. We are seeing an increase in traditional programs making a shift towards medication-assisted treatment (MAT). One of the big three medications used in MAT is naltrexone. Many of these traditional programs are beginning to use or endorse the use of naltrexone because of its non-addictive nature. It’s an effective medication that should be getting as much attention as that of naloxone.
Anti-Drug Addiction Market is a Rapidly Growing Industry
The Food and Drug Administration (FDA) approved Adapt Pharma Ltd.’s NARCAN Nasal Spray formulation in November 2015. Adapt Pharma has signed a licensing deal with Opiant Pharmaceuticals' (OTC:OPNT) (formerly Lightlake Therapeutics) to use its intranasal opioid antagonist platform technology in the development of the NARCAN Nasal Spray. The deal could earn Opiant up to $55 million in milestone payments aside from double-digit percentage royalties from Adapt on NARCAN Nasal Spray sales.
However, Adapt is not the only pharmaceutical company selling NARCAN as an anti-overdose medication. Pfizer’s subsidiary, Hospira, and Amphastar Pharmaceuticals are pioneers in injectable naloxone. These two companies are, in fact, being blamed for the sudden rise in the price of naloxone.
In its latest filing, Amphastar said that naloxone accounted for $38.6 million of the firm’s $251.5 million revenue in 2015, and expects the numbers to rise further as the price of the medication increases. It added that it is currently working on the development of a naloxone nasal spray.
For its part, Kaleo Pharmaceuticals is marketing a naloxone auto-injector under the Evzio brand name at about $700-$800 per dose. Biotech giant, Mylan Inc (NASDAQ:MYL), has started selling a naloxone injectable after receiving FDA approval in 2014. Troubled company, INSYS Therapeutics, is hoping to revive its stock price after getting a naloxone candidate assigned by the FDA as fast track eligible.
Alkermes Plc (NASDAQ:ALKS), a $8.3 billion pharmaceutical company, is offering an injectable naltrexone which is used to block the effects of opioids, at a cost of $1,300 per shot under its Vivitrol brand name. Vivitrol sales reached $55.8 million in the first three quarters of 2016. Alkermes is projecting that the sales of Vivitrol could reach a billion-dollar status in the near future and is looking to reach between $700 million and $800 million sales by 2018.
Last month, Biocorrx Inc (OTC:BICX) announced it would be working with Innovative Science Solutions to assist the company with regulatory matters for the release of its naltrexone injectable product, BICX101, and one or more other naltrexone formularies. BICX101 is currently in preclinical development under BioCorRx’s pharmaceutical subsidiary, in partnership with TheraKine.
BioCorRx’s partnership with Innovative Science Solutions makes its hope of an FDA approval for BICX101 more likely.
Naloxone vs Naltrexone
In the fight against drug addiction, what is the difference between naloxone and naltrexone?
The FDA approved naloxone as a generic drug in 1971. It is often used by first responders and police officers to reverse opioid overdose in an acute situation. Naloxone is being sold as an over-the-counter drug and is sold without a prescription in some states. It can save lives once administered when someone is suspected of overdosing, but it only lasts a short time and the person then needs to be rushed to the hospital for observation. It’s used for overdose and not for long term addiction treatment.
It’s counterpart, naltrexone, is mainly used to reduce cravings and for relapse prevention. If one has therapeutic levels of naltrexone in their system, they can be protected from overdosing as the naltrexone blocks the opioids from binding with the receptors in the brain. BioCorRx is in early stages of development for a new injectable naltrexone called BICX101.
Granier explained, “We believe that any form of sustained release naltrexone is of great benefit in preventing relapse and overdose and the more options we have, the better. BICX101 is being developed with the goal of improving patient compliance by reducing dose volume, needle size, and many other factors which can make compliance with other products more challenging.”
DISCLOSURE: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I have no business relationship with any company whose stock is mentioned in this article.
time to buy more and average down
Validian was "invited" to the Wall St Conference again! for a small fee of 25K - huge news!
My guess is it's that old board member who is no longer involved with the company or just someone flipping who bought in the .03's.
Every year a stock doesn't move is losing money in my book. You could have bought the S&P and crushed it the past 3 years. I guess some people are happy here "VLDI has held strong in the .03's the past 3 years." lol
I have a feeling we are going to break .10 this week and establish a new trading range. An FDA update from the company would be a huge bonus.
I remember them going to the Wall St Conference the last couple of years. It has nothing to do with technology and sounds like a way to get more investors. The Validian broken record plays on again year after year after year with the same tune...
Maybe we will get the IDMC recommendation PR on Tuesday morning.
gold sponsor costs $25,000 for a 20 min presentation
http://wallstconference.com/sponsorship/
http://wallstconference.com/schedule/
Does anyone know if Argos presented yet? Any news?
Looks like we're going into the weekend with no news. Maybe they're going to wait for Tuesday to announce.
People are now maiming their pets to score drugs - that's horrible
https://www.google.com/amp/nypost.com/2017/01/16/people-are-now-maiming-their-pets-to-score-drugs/amp/?client=safari
As if it couldn't get any worse ????
Some of the good stuff the big monkey is smoking...
Awesome! Where can I purchase and download one of these apps?
I bet Trump puts Christie in charge battling this horrible epidemic. If you are reading this Brady, you better get on the phone with Christie ASAP.
Where's the news! Let's go Argos!
We really need some good news here bad. I just fear if it's like one of the usual PR's stock might plummet
so much for our PR today
so much for our PR today
click on your portfolio and then streaming quotes. it's called marketcaster
I get it free with my etrade account. I think most of the online brokers these days offer it for free.
nice bid support in the .07 already today.
44,406,460 x .0001 = $4,440.64
The next PR will have to very very creative.
volume has dried up bad
I bet we get a PR before market open Thursday.
we have been stuck in the .03-.04 range for 6 months so hopefully, this is the new trading range. if anyone is dumb enough to sell shares lower than .06 I will be buying more..
I hope you guys don't actually think these people are paying for those shares??
We made it on SeekingAlpha boys! Getting tons of press!
http://seekingalpha.com/instablog/24380083-komfiem/4959057-massachusetts-angel-program-reducing-cost-drug-addiction-treatment-gets-national-attention
that was fun while it lasted.....
google the first sentence of the post - This was the 4th result..
https://www.thefix.com/content/unintended-consequences-are-we-inadvertently-increasing-heroin-overdose-deaths
.10 just got hit!
IMO this is only the beginning.. We have some great bid support from .06 all the way to .075
I remember taser from years ago. The drug problem in America is at epidemic proportions and IMO the new administration in the White House is taking it very seriously. I wouldn't be surprised if BioCorRx landed a huge government contract sometime in the near future.
The company is supposed to deliver an update on their cancer vaccine P3 trial before the summer. If the news is good IMO the stock should at a minimum trade into the teens.
I heard some rumors of possible combo trials with other drugs. Anyone else hear that?
I've been trading this for about five years. I can tell you the company is 100% legit and that's more than you can say for most of the companies on the OTC. I recently loaded a bunch between .03-.06 And i have no intentions of selling any time soon.
quiet period baby - stealth mode - big things going on behind the scenes......